Partnership Set Up to Address Growing Demand for Self-Administered Therapies

By Felicity ThomasJanuary 23, 20264 min read

A manufacturing collaboration between ten23 health and BD will support the commercialization of a wearable injector platform that offers a ready-to-use option for subcutaneous administration of high-dose biologics.

Swiss-based human-centric CDMO, ten23 health, has entered into a manufacturing collaboration with global medical technology company, BD, to support the commercialization of the BD Libertas wearable injector (1). The partnership, which was announced in a Jan. 20, 2026 press release, will help to address the growing demand for self-administered therapies by providing a scalable, ready-to-use injector platform.

The collaboration agreement will see the BD Libertas wearable injector with a 5 mL or 10 mL BD glass cartridge being supported by ten23 health’s process development, aseptic filling, assembly, and quality control services. As a result of this set up, customers will be able to take advantage of the BD wearable platform and ten23 health’s services when seeking to bring high-volume subcutaneous treatments to the clinic and market.

Additionally, ten23 health’s Line 0 — a robot-assisted pilot non-GMP sterile filling line that the company launched in May 2025 (2) — will be available to customers so that they can test cartridge compatibility, perform stability studies, and optimize filling and stopper setting processes under representative conditions. As Line 0 is a non-GMP pilot line, it is easily accessible and can help to reduce costs usually associated with GMP production.

“Enabling successful patient treatment on behalf of our customers is a key priority for ten23,” said Prof. Dr. Hanns-Christian Mahler, Chief Enablement Officer at ten23 health, in a company press release (1). “Based on the already successful collaboration of ten23 with BD for the BD iDFill solution (RFID-enabled PFS/containers), we are happy to expand our collaboration to also include BD Libertas Wearable Injector platform Our unique offerings and experiences with a range of devices make ten23 an ideal partner for any SC delivery options.”

The companies’ initial collaboration was announced in October 2024 and was aimed at piloting an RFID-based solution to improve manufacturing process efficiency, and provide traceability of individual units (3). End-to-end RFID-enabled syringe traceability was then demonstrated during CPHI Frankfurt in 2025 to allow attendees to experience a full production cycle to see how it can improve safety, quality, and compliance in injectable drug production (4)

References